Thank you for subscribing!
Finfeed Archived May 17, 2017
On May 12, global pharmaceutical group and leading drug developer, AstraZeneca (LON: AZN) announced positive top-line results for the Phase III PACIFIC trial as Imfinzi demonstrated superior progression-free survival (PFS) in ‘all-comer’ patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC), making it the first immuno-oncology medicine to show superior PFS in this setting. The
Finfeed Archived Apr 05, 2017
BARD1 Life Sciences (ASX: BD1) announced on Tuesday that it had entered into a collaboration agreement with the Institute for Respiratory Health (IRH) in order to evaluate the company’s cancer vaccine.
Next Investors Archived Apr 04, 2017
If you are going to beat cancer, your best bet is to catch it early. Of course, that’s easier said than done. By the time the symptoms of many cancers are apparent, a patient is often already in late stages of the disease. This is particularly true for lung cancer.
Finfeed Archived Mar 30, 2017
With one in every two Australians expected to be diagnosed with cancer by age 85, that accounts for about 3 out of every 10 people who will pass away. Looking globally, WHO reported 14.1 million new cases of cancer worldwide in 2012. How to solve the problem? It’s an age-old question that seems to have
Get expert stock analysis direct in your inbox
Next Investors Archived Mar 16, 2017
One in every two Australians will be diagnosed with cancer by age 85. That’s a staggering statistic that has prompted a great deal of contemplation among doctors, patients and those affected in some way by the consequences of the disease. To try and combat the rise and spread of cancer, Big Pharma, along with smaller biotech companies are working on treatments and potential cures. One $30 million capped ASX junior may have a unique solution.
Finfeed Archived Feb 01, 2017
CDY announced that the US Patent and Trademark Office issued Notice of Allowance for the patent its midkine or MK alopecia patent.
Next Investors Archived Jan 24, 2017
Volume is a key word for life sciences play Cellmid (ASX: CDY). Its key hair loss product Evolis® aims to replace thinning hair with voluminous locks, while management seeks to volumise revenues, stock liquidity, and ultimately shareholders’ returns.
Finfeed Archived Nov 18, 2016
“We wanted advisors who will be active participants in the development of NOX66, including running some of our clinical studies, and not just advising from a distance”.
Finfeed Archived Oct 26, 2016
Noxopharm (ASX:NOX) plans to cut the ribbon on its inaugural clinical study of experimental anti-cancer product, NOX66 in December 2016.
Join Our Mailing List
